🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chief Fellow ⁦Riya Patel, MD⁩ proudly sharing her research with Dr. Renuka Iyer at #ASCO24. Using ORIEN data, they uncovered likely biomarkers that can indicate which patients with #cholangiocarcinoma will benefit most from #immunotherapy.

Ahmad Tarhini, MD, PhD (Ahmad Tarhini) presented on how immune cell state atlas can predict the benefits of ICIs in #melanoma treatment. #MoffittASCO24 Learn more: bit.ly/4bRZRrn #ASCO24 ASCO

Today at #ASCO24, Dr. Taylor Rives, Markey Cancer Center, presents collaborative #ORIEN research about molecular differences in Kentucky Appalachian populations which may reveal opportunities for treatment and reduce #cancer disparities. More: meetings.asco.org/abstracts-pres… #CollaborativeScience

GYN oncology fellow, Taylor A. Rives, MD, MD found there are genomic differences in #EndometrialCancer of non-Appalachian & Appalachian patients with increased EVI5 mutations, an oncogene in cell cycle regulation. #ASCO24 Markey Cancer Center

In June, we recognize the strength and resilience of cancer survivors. We celebrate life, spread hope, and continue our commitment to #CancerResearch to improve outcomes for all. Learn from survivors Barney Morris and Deb Collyar why they advocate for patients & cancer research.

Excited to share our latest published article | Differences in Co-Expression of #TCell #CoInhibitory & #CoStimulatory Molecules with #PD1 Across Different Human Cancers | #Immunooncology #DrugDevelopment #ORIEN Moffitt Cancer Center ⁦Moffitt Research⁩ gavinpublishers.com/article/view/d…

The National Cancer Institute Division of Cancer Control & Population Sciences welcomes Dr. Erin Siegel as the new Associate Director of our Epidemiology & Genomics Research Program! Learn more about Dr. Siegel here: epi.grants.cancer.gov/staff/siegel.h…

Happy Independence Day!

Uncover new targets & biomarkers, accelerate clinical trials & more, w/the deepest multimodal dataset for #OncologyResearch & development. • Longitudinal lifetime-consented clinical data • Tumor & Germline DNA • Tumor RNA • Digital pathology ow.ly/hswq50SiosX

New #CancerResearch from our #ORIEN Genitourinary RIG led by Dr. Sumati Gupta, characterizes inherited urothelial cancer risk & emphasizes the significance of comprehensive germline testing in patients w/non-bladder primary disease sites. ascopubs.org/doi/10.1200/PO… #UrothelialCancer

Excited to host Dr. Kimryn Rathmell, NCI Director, as our keynote speaker & Dr. Richard Pazdur, Director, FDA Oncology Center of Excellence, for a fireside chat at our 5th annual #ORIEN Scientific Summit this fall! #CollaborativeScience #OncologyResearch

Industry partners often remark on the depth & quality of Aster data + our unique approach to collaborative research with #ORIEN cancer centers across the U.S. Learn from Dr. Eric Rubin how our solutions informed the early development strategy of Keytruda youtube.com/watch?v=dGDkzg…

Our latest published article |#Melanoma #tumor #microbiome & #TME #immunogenicity, response & resistance to #immunecheckpoint inhibitors | Great collaboration with Dan Spakowicz, AC Tan #ORIEN #IO team | ⁦Moffitt Cancer Center⁩ search.app/GSBjn2AWyemYXU…

📝New publication from Dan Spakowicz & the exORIEN Consortium: The tumor #microbiome as a predictor of outcomes in patients with metastatic #melanoma treated with immune checkpoint inhibitors Ahmad Tarhini #ORIEN Cancer Research Communications doi.org/10.1158/2767-9…

#ICYMI: The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors, by Caroline E. Dravillas et al. bit.ly/3Su8pNj Dan Spakowicz Ahmad Tarhini Ohio State Medical Oncology The James Moffitt Cancer Center #openaccess

On #WorldLungCancerDay, we're proud to be a part of the early development & indication expansion of pembrolizumab, a revolutionary treatment option for many types of cancer, incl. advanced #NSCLC. Our partnerships w/industry, academic cancer centers & patients make this possible.

We collaborate with experts at the nation's top cancer centers to study real-world patient data retrospectively & prospectively. These unique pan-cancer insights accelerate oncology discovery & development and advance cancer care. #CancerResearch #RWD asterinsights.com/solutions/

Scientists across #ORIEN are continually innovating & studying a broad range of topics such as tumor microbiomes, #immuno-oncology, inherited risks, #HealthEquity, #DataScience, #Sarcoma, #BreastCancer, #GI, Thyroid #cancers, and more. asterinsights.com/research/publi…

Longitudinal clinical data w/hundreds of data elements + rich molecular data custom built for oncology discovery + digital pathology images w/AI-powered insights = an unmatched research solution for discovery & clinical development. asterinsights.com/aster-avatar/ #OncologyResearch #RWD

September is Prostate Cancer Awareness Month – Scientists across ORIEN and Aster Insights are working together, armed with Avatar clinicogenomic data, to unlock the complexities of this disease and improve outcomes for men needing novel therapeutic options. G. Daniel Grass MD, PhD